Recursion Pharmaceuticals, Inc.
RXRXHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, Recursion Pharmaceuticals, Inc. (RXRX) is listed under Biotechnology. With a market capitalization of $1.91B, it sits in small-cap territory. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Market Cap
$1.91B
Beta
1.05
P/E (TTM)
—
P/E (Fwd)
-4.09
EPS (TTM)
$-1.16
EPS (Fwd)
$-0.88
ROE
-57.2%
ROA
-27.7%
Cash
$654.5M
Total Debt
$72.4M
Free CF
-$177.8M
52W Change
-17.8%
Annual Financials
Cash vs Debt
With $654.5M in cash and $72.4M in debt, RXRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$177.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -57.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $39.7M (2022) to $74.3M (2025), reflecting a 87% increase over the period.
With cash comfortably exceeding debt, RXRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Recursion Pharmaceuticals, Inc.'s trajectory.